Refractory asthma: Mechanisms, targets, and therapy

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 7, 2014, Pages 817-827

  Trevor, J L ^a   Deshane, J S ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

asthma; glucocorticoids; oxidative stress; refractory; steroid resistance

Indexed keywords

ANTIASTHMATIC AGENT; CORTICOSTEROID; DUPILUMAB; ENOKIZUMAB; GLUCOCORTICOID; HISTONE DEACETYLASE 2; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 23 ANTIBODY; LEBRIKIZUMAB; MEPOLIZUMAB; MUSCARINIC AGENT; PITRAKINRA; THEOPHYLLINE; TRALOKINUMAB;

AIRWAY REMODELING; ASTHMA; GENE TARGETING; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEVERE PERSISTENT ASTHMA; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; DRUG RESISTANCE; IMMUNOLOGY; INFLAMMATION; PHYSIOLOGY;

ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG RESISTANCE; HUMANS; INFLAMMATION;

EID: 84902086943     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12412     Document Type: Review

References (101)

1. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-478. (Pubitemid 38580764)
2. Brannan JD, Lougheed MD,. Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment. Front Physiol 2012; 3: 460.
3. Woodruff PG, Khashayar R, Lazarus SC, Janson S, Avila P, Boushey HA, et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 2001; 108: 753-758. (Pubitemid 33096206)
4. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007; 120 (Suppl 5): S94-S138.
5. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000; 162: 2341-2351.
6. Adcock IM, Caramori G,. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol 2001; 79: 376-384. (Pubitemid 32744283)
7. Liu YJ,. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol 2007; 120: 238-244.
8. Barnes PJ,. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118: 3546-3556.
9. Gleich GJ,. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000; 105: 651-663. (Pubitemid 30226437)
10. Porsbjerg CM, Gibson PG, Pretto JJ, Salome CM, Brown NJ, Berend N, et al. Relationship between airway pathophysiology and airway inflammation in older asthmatics. Respirology 2013; 18: 1128-1134.
11. Niimi A,. Cough, asthma, and cysteinyl-leukotrienes. Pulm Pharmacol Ther 2013; 26: 514-519.
12. Annema JT, Sparrow D, O'Connor GT, Rijcken B, Koeter GH, Postma DS, et al. Chronic respiratory symptoms and airway responsiveness to methacholine are associated with eosinophilia in older men: the Normative Aging Study. Eur Respir J 1995; 8: 62-69.
13. Wark PA, Johnston SL, Moric I, Simpson JL, Hensley MJ, Gibson PG,. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. Eur Respir J 2002; 19: 68-75. (Pubitemid 34105570)
14. Grissell TV, Powell H, Shafren DR, Boyle MJ, Hensley MJ, Jones PD, et al. Interleukin-10 gene expression in acute virus-induced asthma. Am J Respir Crit Care Med 2005; 172: 433-439. (Pubitemid 41117388)
15. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebadze T, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A 2008; 105: 13562-13567.
16. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
17. Hansbro PM, Kaiko GE, Foster PS,. Cytokine/anti-cytokine therapy-novel treatments for asthma? Br J Pharmacol 2011; 163: 81-95.
18. Shaw DE, Berry MA, Hargadon B, McKenna S, Shelley MJ, Green RH, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest 2007; 132: 1871-1875.
19. Vazquez-Tello A, Halwani R, Hamid Q, Al-Muhsen S,. Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells. J Clin Immunol 2013; 33: 466-478.
20. Nakagome K, Matsushita S, Nagata M,. Neutrophilic inflammation in severe asthma. Int Arch Allergy Immunol 2012; 158 (Suppl 1): 96-102.
21. Aujla SJ, Alcorn JF,. T(H)17 cells in asthma and inflammation. Biochim Biophys Acta 2011; 1810: 1066-1079.
22. Zijlstra GJ, Ten Hacken NH, Hoffmann RF, van Oosterhout AJ, Heijink IH,. Interleukin-17A induces glucocorticoid insensitivity in human bronchial epithelial cells. Eur Respir J 2012; 39: 439-445.
23. Roussel L, Houle F, Chan C, Yao Y, Berube J, Olivenstein R, et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 2010; 184: 4531-4537.
24. Linden A,. Role of interleukin-17 and the neutrophil in asthma. Int Arch Allergy Immunol 2001; 126: 179-184. (Pubitemid 34042823)
25. Bousquet J, Chanez P, Lacoste JY, White R, Vic P, Godard P, et al. Asthma: a disease remodeling the airways. Allergy 1992; 47: 3-11.
26. Howell CJ, Pujol JL, Crea AE, Davidson R, Gearing AJ, Godard P, et al. Identification of an alveolar macrophage-derived activity in bronchial asthma that enhances leukotriene C4 generation by human eosinophils stimulated by ionophore A23187 as a granulocyte-macrophage colony-stimulating factor. Am Rev Respir Dis 1989; 140: 1340-1347. (Pubitemid 19276220)
27. Tliba O, Amrani Y,. Airway smooth muscle cell as an inflammatory cell: lessons learned from interferon signaling pathways. Proc Am Thorac Soc 2008; 5: 106-112.
28. Chang PJ, Bhavsar PK, Michaeloudes C, Khorasani N, Chung KF,. Corticosteroid insensitivity of chemokine expression in airway smooth muscle of patients with severe asthma. J Allergy Clin Immunol 2012; 130: 877-885.
29. Deshane J, Zmijewski JW, Luther R, Gaggar A, Deshane R, Lai JF, et al. Free radical-producing myeloid-derived regulatory cells: potent activators and suppressors of lung inflammation and airway hyperresponsiveness. Mucosal Immunol 2011; 4: 503-518.
30. James AL, Maxwell PS, Pearce-Pinto G, Elliot JG, Carroll NG,. The relationship of reticular basement membrane thickness to airway wall remodeling in asthma. Am J Respir Crit Care Med 2002; 166: 1590-1595. (Pubitemid 36015954)
31. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D,. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997; 111: 852-857. (Pubitemid 27171451)
32. Reed CE,. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 1999; 103: 539-547. (Pubitemid 29295555)
33. Ten Hacken NH, Postma DS, Timens W,. Airway remodeling and long-term decline in lung function in asthma. Curr Opin Pulm Med 2003; 9: 9-14. (Pubitemid 35440964)
34. Fixman ED, Stewart A, Martin JG,. Basic mechanisms of development of airway structural changes in asthma. Eur Respir J 2007; 29: 379-389. (Pubitemid 46231919)
35. Pascual RM, Peters SP,. The irreversible component of persistent asthma. J Allergy Clin Immunol 2009; 124: 883-890.
36. Bergeron C, Al-Ramli W, Hamid Q,. Remodeling in asthma. Proc Am Thorac Soc 2009; 6: 301-305.
37. Carroll N, Elliot J, Morton A, James A,. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993; 147: 405-410. (Pubitemid 23044915)
38. Liew FY,. IL-33: a Janus cytokine. Ann Rheum Dis 2012; 71 (Suppl 2): i101-i104.
39. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490. (Pubitemid 41587888)
40. Fujita J, Kawaguchi M, Kokubu F, Ohara G, Ota K, Huang SK, et al. Interleukin-33 induces interleukin-17F in bronchial epithelial cells. Allergy 2012; 67: 744-750.
41. Saglani S, Lui S, Ullmann N, Campbell GA, Sherburn RT, Mathie SA, et al. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol 2013; 132: 676-685.
42. Mauad T, Silva LF, Santos MA, Grinberg L, Bernardi FD, Martins MA, et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 2004; 170: 857-862. (Pubitemid 39346480)
43. Barnes PJ,. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013; 131: 636-645.
44. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E,. The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010; 75: 1-12.
45. Rhen T, Cidlowski JA,. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723.
46. Barnes PJ,. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011; 163: 29-43.
47. Holgate ST, Polosa R,. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368: 780-793. (Pubitemid 44279056)
48. Jarjour NN, Erzurum SC, Bleecker ER, Calhoun WJ, Castro M, Comhair SA, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 2012; 185: 356-362.
49. Carmichael J, Paterson IC, Diaz P, Crompton GK, Kay AB, Grant IW,. Corticosteroid resistance in chronic asthma. Br Med J (Clin Res Ed) 1981; 282: 1419-1422. (Pubitemid 11096240)
50. Jang AS,. Steroid response in refractory asthmatics. Korean J Intern Med 2012; 27: 143-148.
51. Wenzel S,. Severe/fatal asthma. Chest 2003; 123 (Suppl 3): 405S-410S. (Pubitemid 36315437)
52. Silverpil E, Linden A,. IL-17 in human asthma. Expert Rev Respir Med 2012; 6: 173-186.
53. Robinson KM, Manni ML, Biswas PS, Alcorn JF,. Clinical consequences of targeting IL-17 and T17 in autoimmune and allergic disorders. Curr Allergy Asthma Rep 2013; 13: 587-595.
54. Tesmer LA, Lundy SK, Sarkar S, Fox DA,. Th17 cells in human disease. Immunol Rev 2008; 223: 87-113. (Pubitemid 351986173)
55. Cox G,. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995; 154: 4719-4725.
56. Fahy JV,. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc Am Thorac Soc 2009; 6: 256-259.
57. Varga G, Ehrchen J, Tsianakas A, Tenbrock K, Rattenholl A, Seeliger S, et al. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol 2008; 84: 644-650.
58. Petersen BC, Lukacs NW,. IL-17A and IL-25: therapeutic targets for allergic and exacerbated asthmatic disease. Future Med Chem 2012; 4: 833-836.
59. Zhang K, Bai X, Li R, Xiao Z, Chen J, Yang F, et al. Endogenous glucocorticoids promote the expansion of myeloid-derived suppressor cells in a murine model of trauma. Int J Mol Med 2012; 30: 277-282.
60. Gregory LG, Jones CP, Walker SA, Sawant D, Gowers KH, Campbell GA, et al. IL-25 drives remodelling in allergic airways disease induced by house dust mite. Thorax 2013; 68: 82-90.
61. Galliher-Beckley AJ, Williams JG, Cidlowski JA,. Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling. Mol Cell Biol 2011; 31: 4663-4675.
62. Weigel NL, Moore NL,. Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol 2007; 21: 2311-2319. (Pubitemid 47529347)
63. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM,. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002; 109: 649-657. (Pubitemid 34327193)
64. Bhavsar P, Khorasani N, Hew M, Johnson M, Chung KF,. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J 2010; 35: 750-756.
65. Li LB, Goleva E, Hall CF, Ou LS, Leung DY,. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J Allergy Clin Immunol 2004; 114: 1059-1069. (Pubitemid 39469145)
66. Barnes PJ, Karin M,. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071. (Pubitemid 27163860)
67. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ,. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med 1995; 182: 1951-1958.
68. Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006; 203: 7-13. (Pubitemid 43139638)
69. Ito K, Barnes PJ, Adcock IM,. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1 beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000; 20: 6891-6903.
70. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 897-904.
71. Sugiura H, Komaki Y, Koarai A, Ichinose M,. Nitrative stress in refractory asthma. J Allergy Clin Immunol 2008; 121: 355-360.
72. Osoata GO, Hanazawa T, Brindicci C, Ito M, Barnes PJ, Kharitonov S, et al. Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest 2009; 135: 1513-1520.
73. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363: 1715-1726.
74. Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J,. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir Med 2013; 107: 1141-1151.
75. Tomkinson A, Tepper J, Morton M, Bowden A, Stevens L, Harris P, et al. Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma. Allergy 2010; 65: 69-77.
76. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M,. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370: 1422-1431. (Pubitemid 47576168)
77. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455-2466.
78. Garlisi CG, Kung TT, Wang P, Minnicozzi M, Umland SP, Chapman RW, et al. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Biol 1999; 20: 248-255. (Pubitemid 129504884)
79. Liu Y, Zhang S, Li DW, Jiang SJ,. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS ONE 2013; 8: e59872.
80. Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med 2011; 11: 14.
81. Cheng G, Arima M, Honda K, Hirata H, Eda F, Yoshida N, et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 2002; 166: 409-416. (Pubitemid 34864436)
82. Yang G, Li L, Volk A, Emmell E, Petley T, Giles-Komar J, et al. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J Pharmacol Exp Ther 2005; 313: 8-15. (Pubitemid 40411322)
83. Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A,. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med 2010; 10: 3.
84. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
85. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012; 130: 647-654.
86. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013; 41: 330-338.
87. Hellings PW, Kasran A, Liu Z, Vandekerckhove P, Wuyts A, Overbergh L, et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol 2003; 28: 42-50. (Pubitemid 36017049)
88. Anderson GP,. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107-1119.
89. Park SJ, Lee YC,. Interleukin-17 regulation: an attractive therapeutic approach for asthma. Respir Res 2010; 11: 78.
90. Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008; 181: 4780-4790.
91. Pease JE,. Targeting chemokine receptors in allergic disease. Biochem J 2011; 434: 11-24.
92. Fryer AD, Stein LH, Nie Z, Curtis DE, Evans CM, Hodgson ST, et al. Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest 2006; 116: 228-236. (Pubitemid 43121808)
93. Lloyd CM, Brown Z,. Chemokine receptors: therapeutic potential in asthma. Treat Respir Med 2006; 5: 159-166.
94. Mercado N, Hakim A, Kobayashi Y, Meah S, Usmani OS, Chung KF, et al. Restoration of corticosteroid sensitivity by p38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. PLoS ONE 2012; 7: e41582.
95. Berlin AA, Lukacs NW,. Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am J Respir Crit Care Med 2005; 171: 35-39. (Pubitemid 40051692)
96. Barnes PJ,. Biochemical basis of asthma therapy. J Biol Chem 2011; 286: 32899-32905.
97. Barnes PJ,. Theophylline. Am J Respir Crit Care Med 2013; 188: 901-906.
98. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ,. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151: 1907-1914.
99. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181: 116-124.
100. Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa ESJR, Shah PL, et al. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013; 132: 1295-1302.
101. Hakonarson H, Bjornsdottir US, Halapi E, Bradfield J, Zink F, Mouy M, et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci USA 2005; 102: 14789-14794. (Pubitemid 41457134)